CVS to Cover Lilly Weight Loss Drugs Zepbound and Foundayo
CVS Caremark will restore coverage for Lilly's Zepbound on October 1 and add the new obesity pill Foundayo. The move aims to lower costs for health plans.
Xurve View
Insights:
Xurve View
CVS HEALTH CORP will restore coverage for ELI LILLY & CO weight-loss drug Zepbound and add its new obesity pill, Foundayo. The move reverses a July 1 decision to drop Zepbound in favor of NOVO NORDISK A/S-B rival drug Wegovy. It grants Lilly access to 90 million patients in the United States, potentially driving Foundayo sales in the second half of the year.
